Novartis introduces Canada’s Buckley’s cough medicine to U.S. market
PARSIPPANY, N.J. Novartis is bringing Buckley’s, Canada’s No. 1 cough product—according to Information Resources, Inc. data for the 52 weeks ended Aug. 4—to the U.S. market. The brand will be introduced with two SKUs: a cough suppressant mixture and a chest congestion mixture that includes an expectorant.
Buckley’s point of differentiation is its bad taste with the slogan “It tastes awful. And it works.” The cough syrup is both sugar- and alcohol-free and includes camphor, Canadian fir balsam gum, pine needle oil and menthol.
To help generate interest in its U.S. debut, Novartis is sponsoring an online photo contest that invites people to post images of themselves tasting Buckley’s. The contest kicks off Nov. 5 and runs for one month. Entrants will have a chance to win an Alaskan Adventure vacation for two.
“There are two kinds of people in this world—those who what comfort when they are sick and those who want to get better,” stated Jose Rodriguez, Novartis Consumer Health vice president of marketing. “Buckley’s is for people who are focused on getting back to feeling like themsevels again quickly.”
According to Novartis, 65 percent of U.S. households purchased a cough remedy in the last year.
Next, LaValle announce positive results from Seditol study
SALINAS, Calif. Next Pharmaceuticals and The LaValle Metabolic Institute last week announced the results of a clinical study on Seditol, concluding that the natural formulation provides relaxation, promotes restful sleep and helps reduce fatigue due to lack of sleep with minimal side effects.
“I believe that Seditol is a great alternative for people who are interested in a natural approach to managing sleeplessness,” stated Charles Kosmont, chief executive officer and president of Next Pharmaceuticals. “Exhausted Americans filled almost 50 million prescriptions for sleeping pills last year.”
The open-label, single-center trial of 773 people was completed by the LaValle Metabolic Institute in Cincinnati. Of those, 718 reported that Seditol helped them relax; 680 reported Seditol helped them have a restful night’s sleep; and 696 reported Seditol helped reduce fatigue due to lack of sleep.
Warburg Pincus completes B&L acquisition
ROCHESTER, N.Y. Bausch & Lomb and Warburg Pincus on Friday announced that Warburg Pincus has completed the acquisition of B&L for a total purchase price of approximately $4.5 billion, including the assumption of approximately $830 million in debt.
The company’s stock ceased trading on the New York Stock Exchange and was delisted by close of market Friday, the company announced.
“With a strong and supportive partner in Warburg Pincus, we are well-positioned to create new opportunities for Bausch & Lomb and advance our leadership in the eye health industry,” stated Ronald Zarrella, chairman and chief executive officer of B&L. “Our customers will continue to receive high levels of service, product quality and innovation, and our commitment to serving their needs remains steadfast.”